Latest revenue
$8.2M
as of 2026-03-31
Latest net income
$-9.1M
as of 2026-03-31
Net margin
-110.5%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ASMB is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $363.3M
- Enterprise value
- $332.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.83×
- Dividend yield
- 0.0%
- 52-wk high
- $39.70
- 52-wk low
- $15.54
- Beta
- —
- Shares out
- 15.9M
5-year trend
What this company does
Item 1. Business Overview We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPIs) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor; and (3) a highly potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Our pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase…
AI summary unavailable — showing raw filing excerpt
Generated from ASMB's filing dated 2026-03-19
Key risks
Item 1A. Risk Factors You should carefully consider the following risk factors, together with all other information in this report, including our consolidated financial statements and notes thereto, and in our other filings with the SEC. If any of the following risks, or other risks not presently known to us or that we currently believe to not be material, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment. Risks Related to Our Business We have no approved products and depend…
AI summary unavailable — showing raw filing excerpt
Generated from ASMB's filing dated 2026-03-19
Profitability
Operating margin
-16.8%
89.5%Net margin
-8.5%
94.0%Return on equity
-18.4%
84.8%Return on assets
-2.4%
93.0%Leverage
Debt / equity
6.72×
161.3%Debt / assets
87.0%
20.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $8.2M | -12.8% | $-9.1M | -3.0% | -110.5% |
Q4 2025 2025-12-31 | $42.5M | +477.3% | $22.1M | +313.7% | 52.0% |
Q3 2025 2025-09-30 | $10.8M | +57.6% | $-9.2M | +4.3% | -85.2% |
Q2 2025 2025-06-30 | $9.6M | +12.8% | $-10.2M | +8.6% | -105.9% |
Q1 2025 2025-03-31 | $9.4M | +62.8% | $-8.8M | +2.9% | -93.6% |
Q4 2024 2024-12-31 | $7.4M | — | $-10.3M | — | -140.5% |
Q3 2024 2024-09-30 | $6.8M | — | $-9.6M | +33.3% | -140.4% |
Q2 2024 2024-06-30 | $8.5M | — | $-11.2M | +34.0% | -130.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ASMB — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$14.0K
Net activity
−$14.0K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ASMB
Institutional value
$151.6M
Total shares held
5.5M
Distinct holders
20
-49 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 4.5M | $125.0M | +0 (+0.0%) | No change |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 490.4K | $13.6M | — | New |
| 3 | BlackRock, Inc. | 202.7K | $5.6M | +10.4K (+5.4%) | Added |
| 4 | VANGUARD FIDUCIARY TRUST CO | 71.6K | $2.0M | — | New |
| 5 | JPMORGAN CHASE & CO | 54.0K | $1.4M | +5.8K (+12.0%) | Added |
| 6 | JANE STREET GROUP, LLC | 34.5K | $957.3K | -19.2K (-35.8%) | Trimmed |
| 7 | Connor, Clark & Lunn Investment Management Ltd. | 21.8K | $603.9K | +959 (+4.6%) | Added |
| 8 | Palumbo Wealth Management LLC | 19.6K | $545.1K | -17.7K (-47.3%) | Trimmed |
| 9 | FEDERATED HERMES, INC. | 18.9K | $524.6K | -6.5K (-25.6%) | Trimmed |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 17.7K | $491.8K | — | New |
| 11 | Hudson Bay Capital Management LP | 16.8K | $466.2K | +1.7K (+11.6%) | Added |
| 12 | CITIGROUP INC | 6.5K | $179.9K | +4.3K (+194.5%) | Added |
| 13 | Vanguard Global Advisers, LLC | 4.6K | $128.1K | — | New |
| 14 | UBS Group AG | 364 | $10.1K | -9.4K (-96.3%) | Trimmed |
| 15 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 260 | $7.2K | -5.1K (-95.1%) | Trimmed |
| 16 | RHUMBLINE ADVISERS | 190 | $5.3K | +0 (+0.0%) | No change |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 149 | $4.1K | +147 (+7350.0%) | Added |
| 18 | Accent Capital Management, LLC | 142 | $3.9K | — | New |
| 19 | FIFTH THIRD BANCORP | 57 | $1.6K | — | New |
| 20 | GSA CAPITAL PARTNERS LLP | 45.0K | $1.3K | +32.4K (+254.7%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ASMB's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.